Archives

“I don’t dig your cig” : Strategies for tobacco cessation-RECORDED WEBINAR

The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

This year's sympoisum had an overall topic of Drug Induced Disease from a Patient Safety perspective.  This presentation deals with secondary cancers resulting from primary cancer treatment.

Learning Objectives

·  Recall the medicinal uses of tobacco
·  Describe the cycle of tobacco addition
·  Identify strategies for counseling patients on behavioral techniques recommended for tobacco cessation
·   Compare the safety and efficacy of FDA approved pharmacotherapies for tobacco cessation
·    Discuss recommendations from national practice guidelines for tobacco cessation and apply them to a patient case

Activity Release Dates

Released:  April 27, 2023
Expires:  April 27, 2026

Course Fee

$17 Pharmacist

ACPE UAN Codes

 0009-0000-23-012-H01-P

Session Code

23RW12-VXK92

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-23-011-H01-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Stefanie Nigro, PharmD, BCACP, CDCES,
Associate Clinical Professor
Department of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, CT

Faculty Disclosure

Dr. Nigro has no financial relationship with inelegible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test Pharmacist

    1. Which patient characteristic supports initiation of combination therapy for smoking cessation?
      1. Age younger than 65 years
      2. Elevated eosinophil levels
      3. Heavy smoker with high dependence

     

    1. When should patients begin varenicline relative to their quit date if they are following an approach with a traditional fixed quit date?
      1. 1 week prior
      2. 3 days prior
      3. The same day

     

    1. Which of the following treatments for smoking cessation requires a dose adjustment for renal impairment?
      1. Nicotine lozenge
      2. Bupropion SR
      3. Varenicline

     

    1. Which of the following combinations is the most effective for smoking cessation?
    2. Combination NRT
    3. Bupropion SR + nicotine patch
    4. Varenicline + nicotine patch

     

    1. Which statement correctly describes the comparative efficacy of first-line smoking cessation monotherapies?
    2. Bupropion SR is more effective than NRT
    3. All NRTs are more effective than varenicline
    4. Varenicline is more effective than NRT or bupropion SR

     

    1. Why can’t women who are younger than 35 who smoke 15 or more cigarettes per day use estrogen containing contraceptives?
    2. A pharmacokinetic drug interaction decreases contraceptive efficacy and increases risk for adverse effects
    3. A pharmacodynamic drug interaction increases risk of venous thromboembolism, myocardial infarction and stroke
    4. A pharmacokinetic drug interaction increases estrogen levels and also magnifies estrogen-like side effects

     

    1. Patients should be counseled to avoid eating or drinking 15 minutes prior to the use of which therapies?
    2. Nicotine lozenge, gum and inhaler
    3. Nicotine lozenge and gum
    4. Nicotine nasal spray, gum and lozenge

     

     

    1. Which of the following smoking cessation therapies does NOT match with the listed side effect?
    2. Nicotine gum and vivid dreams
    3. Nicotine nasal spray and nasal irritation
    4. Bupropion SR and tremor

     

     

    1. Chad is a 55-year-old male patient with a past medical history including diabetes mellitus type 2, hyperlipidemia, hypertension, and chronic obstructive pulmonary disease. He is currently hospitalized due to a myocardial infarction but is now stable Chad recognizes that quitting smoking is critical to his cardiovascular health and wants to try to quit. Which of the following therapies is a first-line recommendation for Chad to initiate while hospitalized, according to the American College of Cardiology?  

     

    1. Pharmacotherapy is contraindicated 2 weeks post myocardial infarction
    2. Combination therapy with Chantix and NRT
    3. Combination NRT

     

     

    1. Melissa is a 34-year-old female who has smoked two packs per day since she was 19 years old. She comes to the pharmacy and asks if there is a medication that can help her feel ‘readier’ to quit. She does not feel ready to set a quit date but wants to try and work toward this goal. Which of the following medications can Melissa start now with a goal of reducing smoking?
    2. Chantix or NRT
    3. Any of the first-line medications
    4. Bupropion SR

     

     

    Honey: A Sweet Solution?-RECORDED WEBINAR

    The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

    This year's sympoisum had an overall topic of Drug Induced Disease from a Patient Safety perspective.  This presentation deals with secondary cancers resulting from primary cancer treatment.

    Learning Objectives

    • Describe Medicinal History of Honey
    • List Composition and Properties of Honey
    • Identify Diseases and Conditions Treated with Honey
    • Recognize Biologic Activities of Honey

    Activity Release Dates

    Released:  April 27, 2023
    Expires:  April 27, 2026

    Course Fee

    $17 Pharmacist

    ACPE UAN Codes

     0009-0000-23-013-H01-P

    Session Code

    23RW13-KVX29

    Accreditation Hours

    1.0 hours of CE

    Accreditation Statement

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-23-013-H01-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

    Grant Funding

    There is no grant funding for this activity.

    Faculty

    Andrea Hubbard, PhD
    Professor Emeritus
    University of Connecticut School of Pharmacy
    Storrs, CT

    Faculty Disclosure

    Dr. Hubbard has no financial relationship with inelegible companies

    Disclaimer

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Content

    Post Test Pharmacist

        HONEY: A SWEET SOLUTION? Dr. Andrea K. Hubbard

         

        Which of the following is correct?

        1. Propolis helps in the maturation of the queen bee.
        2. Royal jelly helps in the development of the king bee.
        3. Honeybees collect nectar and pollen in separate flights.

         

        How have various people used honey or products of bees for centuries?

        1. Treatment of infected wounds
        2. Element in marriage ritual
        3. Food for livestock

         

         

        What component of honey creates its low pH and antimicrobial activity?

        1. Potassium
        2. Dextrose
        3. Gluconic acid

         

        At what age is it safe to give children honey?

        1. Younger than 1 year of age
        2. Older than 2 years of age
        3. Once they are weaned

         

        Which of the following apitherapy has the FDA-approved?

        1. Propolis
        2. Royal jelly
        3. Honey

         

        Which of the following is a function in honey that is associated with hydrogen peroxide and methylglyoxal?

        1. Vitamin
        2. Mineral
        3. Oxidant

         

        Fill in the blank: Bees lower the water content in honey to _____ through enzymes in their crop, fanning their wings, and keeping their hive at a high temperature.

        1. 25%
        2. 18%
        3. 7%

         

        Ayahuasca and Drug Interaction: The Good, the Bad, the Soul-RECORDED WEBINAR

        The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

        This year's sympoisum had an overall topic of Drug Induced Disease from a Patient Safety perspective.  This presentation deals with secondary cancers resulting from primary cancer treatment.

        Learning Objectives

        The activity met the following learning objectives for Pharmacists:
        ·  Describe pharmacological properties of harmala alkaloids in ayahuasca
        ·  Define adverse reactions associated with food and dietary interactions with ayahuasca such as hypertensive crisis and serotonin toxicity
        ·  Construct management strategies to avoid adverse reactions from interacting foods and drugs
        ·  Discuss observational, clinical, and toxicologic studies relating to ayahuasca use

        Activity Release Dates

        Released:  April 27, 2023
        Expires:  April 27, 2026

        Course Fee

        $17 Pharmacist

        ACPE UAN Codes

         0009-0000-23-009-H05-P

        Session Code

        23RW09-ABC28

        Accreditation Hours

        1.0 hours of CE

        Accreditation Statement

        The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

        Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-23-009-H05-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

        Grant Funding

        There is no grant funding for this activity.

        Faculty

        Benjamin Malcolm, PharmD., MPH
        Psychopharmacology Consultant
        Spirit Pharmacist LLC
        Eugene OR

        Faculty Disclosure

        • Benjamin Malcolm is both an owner and employee of Spirit Pharmacist LLC. He plays an advisor role in exchange for stock in the non-publicly traded company Kaivalya Kollectiv. He functions as a psychopharmacology consultant and has existing financial relationships with several retreat center organizations. He does not own any stock or company that aims to develop pharmaceutical or supplement products.

         

        Disclaimer

        The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

        Content

        Post Test Pharmacist

        Which of the following is true about harmala alkaloid inhibition of MAO?

        1. Harmalas strongly inhibit both MAO-A and MAO-B
        2. Harmalas are irreversible inhibitors of MAO-A
        3. Harmalas are reversible inhibitors of MAO-A

         

        Which of the following is/are red flags for serotonin toxicity when using psychedelics?

        1. Fever > 101F
        2. Dilated pupils
        3. Hallucination

         

        Which of the following drugs do you predict to be dangerous with MAOIs?

        1. A drug that releases serotonin
        2. A drug that increases GABA neurotransmission
        3. A drug that binds to opioid receptors

         

        A new drug named Seratanin has come to market. You research this compound and find that it works by blocking serotonin reuptake, lacks active metabolites, and has an elimination half life of ~48 hours. Which of the following do you predict?

        1. It could be dangerous with ayahuasca if not avoided for at least 10 days prior
        2. It could be dangerous with ayahuasca if not avoided at least 48 hours prior
        3. It could be dangerous with ayahuasca if not avoided at least 6 days prior

         

        Why is it difficult to analyze calls made to poison control centers concerning Ayahuasca?

        1. Poison control centers have received fewer than 100 calls since they started tracking so any assumption lacks statistical significance
        2. Poison control centers have been unable to verify contents of ayahuasca or other concurrent drugs users were taking
        3. Most of the calls come from older women, reflecting the Baby Boomers propensity to be more accepting of hallucinogens

        Evidence Based LDL Lowering Options-RECORDED WEBINAR

        The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

        This year's sympoisum had an overall topic of Drug Induced Disease from a Patient Safety perspective.  This presentation deals with secondary cancers resulting from primary cancer treatment.

        Learning Objectives

        The activity met the following learning objectives for Pharmacists:
        ·    Describe the role of dietary modification for LDL modification

         
        ·       Identify how some dietary supplement ingredients mimic the mechanisms of action of prescription drugs
        ·       Describe the magnitude of plant sterols and stanols, red yeast rice, silybum M, berberine, cinnamon, green tea extract, and garlic LDL reduction as monotherapy
        ·       Describe the potential for combination therapy to increase the magnitude of benefit
        ·       Compare and contrast with prescription LDL lowering options
        ·  Describe risks of contamination and adulteration with dietary supplements

        Activity Release Dates

        Released:  April 27, 2023
        Expires:  April 27, 2026

        Course Fee

        $17 Pharmacist

        ACPE UAN Codes

         0009-0000-23-010-H01-P

        Session Code

        23RW10-CBA96

        Accreditation Hours

        1.0 hours of CE

        Accreditation Statement

        The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

        Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-23-010-H01-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

        Grant Funding

        There is no grant funding for this activity.

        Faculty

        C. Michael White, PharmD, FCCP, FCP
        Professor and Department Head Pharmacy Practice
        University of Connecticut School of Pharmacy and Director HOPES Research Group
        Storrs, CT

        Faculty Disclosure

        Dr. White is a co-investigator on a project assessing the risk of bias for an anti-bleeding drug, andexanet alfa. This is a bleeding reversal agent and AstraZeneca is funding it. They do not have a lipid reducing product that I am discussing in this presentation or as a competitor to the products I am discussing.  nonetheless.

        Disclaimer

        The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

        Content

        Post Test Pharmacist

        1. Which of the following fats has the worst effects on the LDL to HDL ratio?
        2. Trans fats
        3. Saturated fats
        4. MUFAs

         

        1. Which of the following describes the impact of the Mediterranean diet on patients?
        2. It reduces cardiovascular events significantly and LDL by a large amount
        3. It reduces cardiovascular events significantly and LDL to a modest amount
        4. It reduces the need for lipid lowering therapy by a large amount

         

        1. Which of the following supplements is linked correctly to its likely mechanism of action?
        2. Berberine – Blocks the enzyme HMG CoA Reductase
        3. Red Yeast Rice – Blocks formation of the protein PCSK9
        4. Sterols/Stanols – Block LDL reabsorption and fat absorption

         

        1. Tobias Whale is a 50-year-old super villain in the series Black Lightening. In addition to killing the innocent and extorting small business owners, he also has a poor baseline diet. He requires a 6% reduction in his LDL to reach his goal. Which of the following natural products are MOST LIKELY to get him to goal?
        2. Cinnamon
        3. Green tea
        4. Red Yeast Rice

         

        1. What does a USP or NSF seal on a bottle of Red Yeast Rice tell you?
        2. That the product will reduce your LDL by 30% under normal circumstances
        3. That the product will reduce your risk of ASCVD events
        4. That the specified active ingredient is actually in the pills

         

        Arthur E. Schwarting Symposium LIVE Event 2026 – TBD

        The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

        Arthur E. Schwarting Symposium 2026

        Five hours of live CE

        REGISTER NOW

        2025 Schwarting Agenda

        11:00am-12:00 pm  Information overload to action: Decoding academic concepts for pharmacy preceptors
        Jennifer Luciano, PharmD, Director Office of Experiential Education, University of Connecticut School of Pharmacy, Storrs, CT

        At the end of this presentation the learner will:

        • Discuss how ACPE standards, the NAPLEX blueprint, and Entrustable Professional Activities (EPAs) guide the development of clinical competence in students, specifically in the context of patient care.
        • Describe the Pharmacist Patient Care Process (PPCP) and its key components.
        • Explain how the PPCP framework is applied in experiential education and clinical rotations.

        ACPE UAN: 0009-0000-25-026-L04-P                                     Application

        12:05-1:05 pm   Patient Safety: Anticoagulation Stewardship: Identifying Key Data, Avoiding Errors, and Enhancing Safety
        Youssef Bessada, PharmD, BCPS, BCPP, Assistant Clinical Professor,UConn School of Pharmacy, Storrs, CT

        At the end of this presentation the learner will:

        • Differentiate high-priority, practice-changing information from less relevant or conflicting data after reviewing the anticoagulation guidelines, literature and clinical updates.
        • Recognize common anticoagulation-related errors in pharmacy practice and implement strategies to minimize patient safety risks
        • Identify red flag situations in anticoagulation management that pose patient safety risks.
        • Determine the appropriate guidelines or evidence-based resources to guide clinical decision-making and referrals

        ACPE UAN: 0009-0000-25-029-L05-P             Application

        1:10-2:10 pm  Information Overload in Chronic Coronary Disease
        Michael White, PharmD, FCCP, FCP, BOT Distinguished Professor and Chair of Pharmacy Practice University of Connecticut School of Pharmacy, Storrs, CT

        At the end of this presentation the learner will:

        • Determine if a patient has chronic cardiac disease (CCD).
        • Identify lifestyle modifications that can reduce the risk of CCD.
        • Identify therapies that can reduce final health outcomes for specific CCD patient types to design successful drug regimens.
        • Describe how the steps in the PPCP process can be applied when reviewing a cardiac patient.

        ACPE UAN:  0009-0000-25-028-L01-P            Application

        2:15-3:15 pm Law: Understanding Disabled Pharmacy Patients’ Right to Nondiscrimination
        Caroline Wick, JD, MSPH, BA, Practitioner-in-Residence and Acting Director of the Disability Rights Law Clinic, American University Washington College of Law, Washington DC 

        At the end of this presentation the learner will:

        • Describe the federal and state laws that protect patients with disabilities
        • Recognize situations in which accommodations should be provided to disabled patients
        • Recall examples of common modifications for patients with disabilities

        ACPE UAN: 0009-0000-25-027-L03-P            Knowledge

        3:20-4:20 pm- So Much STI Data: Information to help you stay current and informed
        Jennifer Girotto, PharmD, BCPPS, BCIDP, Associate Clinical Professor, UConn School of Pharmacy, Storrs, CT

        At the end of this presentation the learner will

        • Describe updated screening recommendations and epidemiological trends of sexually transmitted infections (STIs).
        • Review the Centers for Disease Control and Prevention’s STIs recommendations.
        • Explain latest evidence based STI updates.
        • Given medication shortages, outline the pharmacist’s role in delivering targeted patient education and implementing strategies for responsible medication stewardship for STIs.

        ACPE UAN: 0009-0000-25-030-L01-P             Application

         

        Handouts will be posted 72 hours prior to the event  in 2 slide/page and 6 slide/page below:

        11:00am-12:00 pm    Information overload to action: Decoding academic concepts for pharmacy preceptors     2 slides/page
                                                 Information overload to action: Decoding academic concepts for pharmacy preceptors     6 slides/page

        12:05-1:05 pm           Patient Safety: Anticoagulation Stewardship: Identifying Key Data, Avoiding Errors, and Enhancing Safety   2 slides/page
                                                 Patient Safety: Anticoagulation Stewardship: Identifying Key Data, Avoiding Errors, and Enhancing Safety     6 slides/page

        1:10-2:10 pm         Information Overload in Chronic Coronary Disease – 2 slides/page
                                           Information Overload in Chronic Coronary Disease – 6 slides/page

        2:15-3:15 pm          Law: Understanding Disabled Pharmacy Patients’ Right to Nondiscrimination 2 slides/page
                                             Law: Understanding Disabled Pharmacy Patients’ Right to Nondiscrimination 6 slides/page                 

        3:20-4:20 pm     So Much STI Data: Information to help you stay current and informed – 2 slides/page
                                        So Much STI Data: Information to help you stay current and informed – 6 slides/page

        ACPE Logo“The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.”

         

         

         

        Law: Psychedelic Drugs: Can They Make the “Trip” to the Pharmacy Shelf?-RECORDED WEBINAR

        The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

        This year's sympoisum had an overall topic of pharmcogenesy which was a favorite area of Dean Schwarting's.  This presentation is a Law CE revolving around psychodelic drugs used to treat Mental Health Disorders.

        Learning Objectives

        1. Review the development of the knowledge of the effects of psychedelic drugs and their potential use in
        psychiatry, with an emphasis on psilocybin.
        2. Characterize the traditional legal classification of psychedelic drugs and modern reconsideration of their legal
        status.
        3. Describe efforts at the state level to expand the medical use of psychedelic drugs.

        Session Offered

        Released:  April 27, 2023
        Expires:  April 27, 2026

        Course Fee

        $17 Pharmacist

        ACPE UAN Codes

         0009-0000-23-011-H03-P

        Session Code

        23RW11-TXJ88

        Accreditation Hours

        1.0 hours of CE

        Accreditation Statement

        The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

        Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-22-017-H03-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

        Grant Funding

        There is no grant funding for this activity.

        Faculty

        Gerald Gianutsos, PhD, JD,
        Professor Emeritus
        University of Connecticut School of Pharmacy
        Storrs, CT 

        Faculty Disclosure

        Dr. Gianutsos has no financial relationships with any ineligible company associated with this presentation.

        Disclaimer

        The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

        Content

        Handouts

        Download

        Post Test Pharmacist

        Schwarting Webinar 2023 Post-Test

         

          1. Review the development of the knowledge of the effects of psychedelic drugs and their potential use in psychiatry, with an emphasis on psilocybin.
          2. Characterize the traditional legal classification of psychedelic drugs and modern reconsideration of their legal status.
          3. Describe efforts at the state level to expand the medical use of psychedelic drugs.

         

        The tryptamine class of psychedelic drugs (e.g., LSD, psilocybin) produce their psychedelic/therapeutic effects by acting as agonists of a neurotransmitter in the CNS. What is the relevant neurotransmitter system?

         

        1. Serotonin
        2. Dopamine
        3. Glutamate

         

         

        The FDA granted “breakthrough therapy” designation to psilocybin for treatment of a specific condition. What condition is it?

        1. Schizophrenia
        2. Treatment resistant depression
        3. Post traumatic stress disorder

         

         

         

        Which feature distinguishes a C-I drug from other controlled substances?

        1. High potential for abuse, especially among hi-riskpopulations
        2. Lack of accepted safety for use under medical supervision
        3. No currently accepted medical use in treatment in the United States

         

         

        Which state was the first to approve the use of psilocybin for medical use?

        1. California
        2. Oregon
        3. Maryland

         

         

        A patient considering psilocybin treatment for a psychiatric disorder asks you for advice; he is specifically interested in disadvantages of this type of therapy. What do you tell him?

        1. Use of psychedelic therapy is time-and resource-intensive
        2. Requires multiple treatments with a slow onset of activity
        3. There is a high risk of autonomic side effects and addiction

         

         

        In the state where medical use of psilocybin was first approved, which of the following statements describes its availability?

        1. Psilocybin can be purchased at retail outlets including pharmacies
        2. Psilocybin is available from any therapist throughout the state
        3. Psilocybin is only available in state licensed clinics